RAS is the most frequently mutated oncogene in human cancer. Scientists 
attempted for decades to target this protein or its pathways, however, all the 
attempts failed and RAS was labeled as "undruggable". With KRAS-G12C covalent 
inhibitors entering clinical trials, the myth of this "undruggable" RAS is 
fading away. In 2021, the Food and Drug Administration (FDA) approved the use of 
Sotorasib (Lumakras) for the treatment of adult patients with KRAS-G12C mutated 
locally advanced or metastatic NSCLC, following at least one prior systemic 
therapy. However, and as every other drug, KRAS-G12C inhibitors are facing 
intrinsic and acquired resistances. In order to overcome these resistances, 
researchers are now working on combination strategies. Furthermore, studies are 
currently ongoing to better elucidate the status of KRAS-G12C as a predictive 
and prognostic tool and to strengthen its role in the field of personalized 
medicine.